Beida Pharmaceuticals can break the problem list alone.

Pharmaceutical Network June 18th, June 14th, Beida Pharmaceuticals' application for the listing of Beva zhussssssssm sepsis injections for the treatment of advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer was accepted by the State Drug AdministrationFor a long time, the over-reliance on a single product has called for Beida Pharmaceuticals' ability to resist risks, and with the listing of Beval-Zhusing mono-injection injections, Beida Pharmaceuticals has ushered in a harvest period and is expected to change the single-product situationHowever, at present, a number of domestic and foreign enterprises related products have been approved or submitted the relevant drug registration application, Beval zhu sing-toting injection can break the company's single-product situation, but also to see the follow-up sales capacity of Beida Pharmaceuticals.Expanding the product line
Beval bead sing-it injection is expected to enrich the Beida Pharmaceutical product lineAccording to a notice issued by Beida Pharmaceuticals, the Company received a "Receiving Notice" issued by the State Drug Administration (NOCXSS200027), and the Company's declared Beva Zhusing sing-up injection ("MIL60", Avastin's biosimilar drug) for the treatment of patients with advanced, metastatic or recurrent non-small cell and metastatic colorectal cancer has been accepted by the State Drug Administration.Because of china's first small molecule with independent intellectual property rights targeted anti-cancer drugs, Beida Pharmaceuticals has attracted much attentionData show that Beida Pharmaceuticals was founded by DrHaihui, with independent intellectual property rights innovation drug research and development as the core, setpharmaceuticalresearch and development, production, marketing in one.In 2011, Beida Pharmaceuticals independently developed the national 1.1 new drug Ektini by the State Drug Administration issued a new drug certificate and production approval and began to market sales, this is China's first with independent intellectual property rights of small molecule-targeted anti-cancer drugs .　　Beida Pharmaceuticals this time received the acceptance of the Beval-Zhusing mono-anti-injection injection by Roche original research Bevazumab is a recombinant human-derived anti-vascular endothelial growth factor (VEGF) monoantithetic, which inhibits tumor suppression by blocking the binding of VEGF to VEGF receptors on the surface of vascular endothelial cells, thereby inhibiting the conduction of PI3K-Akt/PKB and Ras-Raf-MEK-ERK signaling pathways, blocking the generation and blood supply of new blood vessels in tumors In February 2010, Beval Zuma was approved for listing in China According to Zhongkang data, sales of Bevalzumab in China in 2018 were RMB2,731 million, up 54.2% YoY .　　In an interview with reporters, the MIL60 project is the company's first large-molecule biosimilar drug to declare BLA, which will not only expand the company's product layout in the field of lung cancer treatment, but also benefit from the experience gained from the project in the development of subsequent macromolecule biopharmaceuticals .　　Long-term single-product performance due to the long time of research and development of new drugs and other factors, since 2011, Beida Pharmaceuticals' main revenue source is relying on ektini products In 2016-2018, Beda Pharmaceuticals' Ektini achieved revenue of RMB1.035 billion, RMB1.026 billion and RMB1.208 billion, respectively, with revenue accounting for 99.98 percent, 99.96 percent and 98.72 percent, respectively In 2017, Beida Pharmaceuticals' revenue decreased by 0.84% YoY and net profit decreased by 30.12% YoY .　　According to Beida Pharmaceuticals, the decline in the company's performance is mainly due to the core product seinib in various places to implement the national health insurance negotiated prices, product price reduction is larger, and the amount of health insurance brought by the release has not been clearly reflected At the same time, the company's new drug research and development work to step up, research and development investment increased more .　　In 2018, Beida Pharmaceuticals adjusted the price of Ektini's provincial hanging net, and the hydrochloric acid ektini tablets (125mg x 21 tablets/box) were adjusted from 66.62 yuan/piece, 1399 yuan/box to 64.05 yuan/piece, 1345.05 yuan/box After two price cuts in 2016 and 2018, the price of a single-box drug from Ektini fell from $3,080 to $1,345.05, a 56% reduction In the same year, Beida Pharmaceuticals' net profit fell by 35% year-on-year to 167 million yuan, after falling for two consecutive years Among them, sales of core products, Ektini, increased by 30.45 per cent year-on-year to 104.78 million boxes, but gross margin decreased by 0.47 per cent to 95.27 per cent .　　In 2019, the effects of Ektini's entry into health insurance for price-for-value are apparent During the year, Beida Pharmaceuticals achieved revenue of RMB1.554 billion, up 26.94 percent year-on-year, while net profit increased 38.37 percent year-on-year to RMB231 million .　　However, in the face of fierce market competition, the single-product-only Beida Pharmaceuticals anti-risk ability is in doubt AstraZeneca's Gifitini and Roche's Erotini are both strong rivals for Ecclestone In the 2018 promotion of the national 4-7 belt procurement , The gifitini will reduce the original price of 2000 yuan / box to 547 yuan / box, the price reduction of 75% .　　Beida Pharmaceuticals is also aware that its long-term reliance on a product has made the company less risk-averse and accelerated the launch of new products Beida Pharmaceuticals officials told reporters that the company in the new drug hydrochloric acid ensatinib (Bemena) has been completed in 2019 clinical verification, is currently in the priority review "With continuous research and development investment, the company's product line has become increasingly rich, laying a solid foundation for long-term growth." .　　According to the financial results, in 2017-2018, The research and development investment of Beida Pharmaceuticals was RMB380 million, RMB 590 million and RMB675 million, respectively, accounting for 37.09%, 48.2% and 43.41% of operating income, respectively .　　Sales capacity to be tested
this Bevalzhu single anti-injection liquid listing application to be accepted will hopefully break the situation of Beida Pharmaceuticals single product Zhao Heng, founder of Latitude Health, a medical strategy consulting firm, told reporters that if Beval-Zhusing's single-injection injections can be successfully listed, The long-term reliance on single-product Ektini to support performance will be expected to ease, but specifically depends on The following sales capacity of Beida Pharmaceuticals .　　Up to now, there are two domestic Bevala bead singogen singogen singic injections listed, one is developed by Roche of Switzerland Bevebead monoantigen research drug, and the other is developed by Qilu Pharmaceuticals, the first domestic approved bewarzumab biosimilar drug .　　From the patient's needs, lung cancer and colorectal cancer have become the first and third largest cancer species in China, respectively Data show that there were about 774,000 new cases of lung cancer in China in 2018; Colorectal cancer is second only to lung and stomach cancer in China, with 429,000 new cases and 281,000 deaths in 2018 According to Sullivan, with the continued introduction of biosimilar drugs and the combination of belaval singofa and other drugs, the domestic market size of belaval singj is expected to reach 17.7 billion yuan by 2030 .　　The expanding size of the drug market has attracted many enterprises to layout In addition to the two drugs listed above, Cinda Bio, Shandong Green Leaf, Jiangsu Hengrui has also submitted the relevant drug registration application, are currently in the state of review .　　Beida pharmaceutical industry related person in charge said that the company Bevalju singofa injection (MIL60) still need to carry out a series of approval work for the listing of new drugs, during the bayabead sing-it-againstre injection market pattern may also be various changes, after the new drug was approved for listing, the company will be based on the market situation at that time reasonable pricing .